Research Papers:
Expression of uc.189 and its clinicopathologic significance in gynecological cancers
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1385 views | HTML 2149 views | ?
Abstract
Lei Wang1,2,6,*, Xing Cheng Wang2,6,*, Xinyu Li3,6,*, Yan Gu4, Jun Zhou1, Shuwan Jiang1, Jiajia Liu1, Chong Wu1,*, Zhiyan Ding1, Yafeng Wan2,6,* and Chenghai Wang1,2,4,5,6
1Department of Pathology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, China
2Department of Pharmacy, Medical College, Yangzhou University, Yangzhou, Jiangsu 225001, China
3Department of Basic Medical, Medical College, Yangzhou University, Yangzhou, Jiangsu 225001, China
4Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu 225001, China
5Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, Jiangsu 225001, China
6Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, Jiangsu 225009, China
*These authors contributed equally to this work
Correspondence to:
Chenghai Wang, email: [email protected]
Keywords: gynecological cancers; cervical squamous cell carcinoma; endometrial adenocarcinoma; uc.189; prognosis
Received: April 04, 2017 Accepted: December 23, 2017 Published: December 29, 2017
ABSTRACT
In recent decades, emerging evidence demonstrates that ultraconserved elements (UCEs) encoding noncoding RNAs serve as regulators of gene expression. Until now, the role of uc.189 in human cancers remains undefined and the clinical significance of uc.189 in gynecological cancers remains unknown. This study was to identify the prognostic value of uc.189 expression in gynecological cancers. Tissue microarrays were constructed with 243 samples including 116 cervical squamous cell carcinomas (CSCCs), 98 endometrial adenocarcinomas (EACs), 29 ovarian cystoadenocarcinomas(OCAs), and corresponding normal tissues. In CSCC, uc.189 expression was increased in 78.5% of cases (91/116), decreased in 4.3% (5/116), and unchanged in 17.2% (20/116). In EAC its expression was increased in 74.5% (73/98), decreased in 3.1% (3/98), and unchanged in 22.4% (22/98). Expression of uc.189 was increased in 23, and unchanged/decreased in 6, of 29 cases of ovarian cystoadenocarcinomas. Univariate and multivariate Cox regression analysis demonstrated that over-expression of uc.189 predicted poor prognosis in CSCC and EAC. Thus, these findings suggested uc.189 might be an evaluating prognosis marker of gynecological tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23761